31.85USD+0.19%Mkt Cap: 1.52B USDP/E: —Last update: 2026-05-22
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidat…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap1.52B USD
Enterprise Value1.07B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-86.97M USD
Revenue/Share—
Last Price31.85 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees63
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.06
PEG—
EV/EBITDA-10.89
EV/Revenue—
P/S—
P/B3.45
EPS (TTM)-2.17
EPS (Forward)-3.94
52W Range
9.43062% of range45.85
52W High45.85 USD
52W Low9.430 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-23.56%
ROA-22.58%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-79.95M USD
CapEx (TTM)1.93M USD
FCF Margin—
FCF Yield-3.46%
Net Debt-439.42M USD
Net Debt/EBITDA4.46
Balance Sheet
Debt/Equity0.00
Current Ratio30.79
Quick Ratio30.42
Book Value/Sh9.202 USD
Cash/Share9.244 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)69.09 USD
Target Range20.00 USD – 91.00 USD
# Analysts11
Ownership
Shares Out.47.60M
Float29.61M
Insiders2.70%
Institutions111.47%
Short Interest
Short Ratio8.7d
Short % Float11.90%
Short % Out.8.48%
Shares Short4.03M
Short (prev mo.)3.59M
Technical
SMA 5031.54 (+1.0%)
SMA 20026.67 (+19.4%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)619.38K
Avg Vol (10d)988.43K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—